Cargando…

Correction: Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357792/ https://www.ncbi.nlm.nih.gov/pubmed/37463791 http://dx.doi.org/10.1136/jitc-2021-004043corr1

Ejemplares similares

Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents
por: Turiello, Roberta, et al.
Publicado: (2022)

Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy
por: Turiello, Roberta, et al.
Publicado: (2020)

Correction: The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow
por: Lange, Andrzej, et al.
Publicado: (2018)

Correction to: CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma
por: Rocha, Pedro, et al.
Publicado: (2021)

Author Correction: CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas
por: Niborski, Leticia Laura, et al.
Publicado: (2023)

Correction: CD73 Expressed on γδ T Cells Shapes Their Regulatory Effect in Experimental Autoimmune Uveitis
por: Liang, Dongchun, et al.
Publicado: (2016)

Correction: CD73 Is Dispensable for the Regulation of Inflationary CD8(+) T-Cells after Murine Cytomegalovirus Infection and Adenovirus Immunisation
Publicado: (2015)

Correction: The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth
por: Hanson, Kimberley, et al.
Publicado: (2018)

CD73 is involved in lymphocyte binding to the endothelium: characterization of lymphocyte-vascular adhesion protein 2 identifies it as CD73
Publicado: (1995)

CD73 Promotes Chronic Lymphocytic Leukemia
por: Allard, David, et al.
Publicado: (2022)

Correction: Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy
por: Fumet, Jean-David, et al.
Publicado: (2019)

Correction to: JNK–NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress
por: Kostecka, A., et al.
Publicado: (2018)

Correction to: Contributions of T cell dysfunction to the resistance against anti-PD-1 therapy in oral carcinogenesis
por: Wen, Liling, et al.
Publicado: (2022)

Correction: CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
Publicado: (2022)

Correction to Lancet Gastroenterol Hepatol 2020; 5: 362–73
Publicado: (2020)

Correction: Reactivation of low avidity tumor-specific CD8+ T cells associates with immunotherapeutic efficacy of anti-PD-1
Publicado: (2023)

Correction: Characterization of Ectonucleotidases in Human Medulloblastoma Cell Lines: ecto-5′NT/CD73 in Metastasis as Potential Prognostic Factor
por: Cappellari, Angélica Regina, et al.
Publicado: (2012)

Correction to: Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents Iris
por: Hagemans, Iris M., et al.
Publicado: (2022)

Correction: Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
Publicado: (2022)

Adriamycin‐loaded exosome with anti‐CD20 aptamers selectively suppresses human CD20+ melanoma stem cells
por: Chen, Hairong, et al.
Publicado: (2022)

Correction: Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1- immunotherapy in colon cancer
Publicado: (2021)

Correction: CD40 Activation Rescues Antiviral CD8(+) T Cells from PD-1-Mediated Exhaustion
por: Isogawa, Masanori, et al.
Publicado: (2016)

Correction: CD40 Activation Rescues Antiviral CD8(+) T Cells from PD-1-Mediated Exhaustion
por: Isogawa, Masanori, et al.
Publicado: (2017)

CD73 expression and clinical significance in human metastatic melanoma
por: Monteiro, Inês, et al.
Publicado: (2018)

Correction: Tumor-derived exosomes induce PD1(+) macrophage population in human gastric cancer that promotes disease progression
por: Wang, Furong, et al.
Publicado: (2022)

Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC
por: Tu, Eric, et al.
Publicado: (2022)

Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73(-) Phenotype Identifies Polyfunctional Cytotoxic Lymphocytes
por: Ahmadi, Parimah, et al.
Publicado: (2020)

Correction to: Dynamic serum biomarkers to predict the efficacy of PD-1 in patients with nasopharyngeal carcinoma
por: Zhang, Ao, et al.
Publicado: (2021)

Correction to: Exosomes in Cardiovascular Medicine
por: Dykes, Iain M.
Publicado: (2018)

Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
por: Ren, Daixi, et al.
Publicado: (2020)

Correction: Depletion of Regulatory T Cells Induces High Numbers of Dendritic Cells and Unmasks a Subset of Anti-Tumour CD8(+)CD11c(+) PD-1(lo) Effector T Cells
por: Goudin, Nicolas, et al.
Publicado: (2017)

Correction to: Anti-migraine agents from an immunological point of view
por: Assas, Mushref Bakri
Publicado: (2021)

Correction: Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy
por: Liu, Can, et al.
Publicado: (2019)

Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28
por: Zhang, Chaoxu, et al.
Publicado: (2020)

Correction: Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)
Publicado: (2022)

Correction to: context-dependent AMPK activation distinctly regulates TAp73 stability and transcriptional activity
por: Li, Dan, et al.
Publicado: (2021)

Correction: Exosomal Wnt-induced dedifferentiation of colorectal cancer cells contributes to chemotherapy resistance
por: Hu, Y.-B., et al.
Publicado: (2019)

Correction to: Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
por: Brogden, Kim A., et al.
Publicado: (2018)

CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer
por: Cao, Lu, et al.
Publicado: (2022)

Author Correction: Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors
por: Smolarczyk, Ryszard, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q0elube67cfdq3jl091jpip6ck